These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27079849)

  • 1. Rational Design of Proteasome Inhibitors as Antimalarial Drugs.
    Le Chapelain C; Groll M
    Angew Chem Int Ed Engl; 2016 May; 55(22):6370-2. PubMed ID: 27079849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.
    Zhan W; Zhang H; Ginn J; Leung A; Liu YJ; Michino M; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Chelebieva S; Tumwebaze PK; Lafuente-Monasterio MJ; Martinez-Martinez MS; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Meinke PT; Nathan CF; Kirkman LA; Lin G
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9279-9283. PubMed ID: 33433953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
    Li H; Bogyo M; da Fonseca PC
    FEBS J; 2016 Dec; 283(23):4238-4243. PubMed ID: 27286897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
    Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
    Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution cryo-EM proteasome structures in drug development.
    Morris EP; da Fonseca PCA
    Acta Crystallogr D Struct Biol; 2017 Jun; 73(Pt 6):522-533. PubMed ID: 28580914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome.
    Li H; Tsu C; Blackburn C; Li G; Hales P; Dick L; Bogyo M
    J Am Chem Soc; 2014 Oct; 136(39):13562-5. PubMed ID: 25226494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.
    LaMonte GM; Almaliti J; Bibo-Verdugo B; Keller L; Zou BY; Yang J; Antonova-Koch Y; Orjuela-Sanchez P; Boyle CA; Vigil E; Wang L; Goldgof GM; Gerwick L; O'Donoghue AJ; Winzeler EA; Gerwick WH; Ottilie S
    J Med Chem; 2017 Aug; 60(15):6721-6732. PubMed ID: 28696697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of Asparagine Ethylenediamines as Anti-malarial
    Zhan W; Visone J; Ouellette T; Harris JC; Wang R; Zhang H; Singh PK; Ginn J; Sukenick G; Wong TT; Okoro JI; Scales RM; Tumwebaze PK; Rosenthal PJ; Kafsack BFC; Cooper RA; Meinke PT; Kirkman LA; Lin G
    J Med Chem; 2019 Jul; 62(13):6137-6145. PubMed ID: 31177777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trioxaferroquines as new hybrid antimalarial drugs.
    Bellot F; Coslédan F; Vendier L; Brocard J; Meunier B; Robert A
    J Med Chem; 2010 May; 53(10):4103-9. PubMed ID: 20443628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome as a target to combat malaria: hits and misses.
    Krishnan KM; Williamson KC
    Transl Res; 2018 Aug; 198():40-47. PubMed ID: 30009761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria.
    Lawong A; Gahalawat S; Ray S; Ho N; Han Y; Ward KE; Deng X; Chen Z; Kumar A; Xing C; Hosangadi V; Fairhurst KJ; Tashiro K; Liszczak G; Shackleford DM; Katneni K; Chen G; Saunders J; Crighton E; Casas A; Robinson JJ; Imlay LS; Zhang X; Lemoff A; Zhao Z; Angulo-Barturen I; Jiménez-Díaz MB; Wittlin S; Campbell SF; Fidock DA; Laleu B; Charman SA; Ready JM; Phillips MA
    Cell Chem Biol; 2024 Aug; 31(8):1503-1517.e19. PubMed ID: 39084225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantiomeric 1,2,4-trioxanes display equivalent in vitro antimalarial activity versus Plasmodium falciparum malaria parasites: implications for the molecular mechanism of action of the artemisinins.
    O'Neill PM; Rawe SL; Borstnik K; Miller A; Ward SA; Bray PG; Davies J; Oh CH; Posner GH
    Chembiochem; 2005 Nov; 6(11):2048-54. PubMed ID: 16222725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent Macrocyclic Proteasome Inhibitors Mitigate Resistance in
    Bennett JM; Ward KE; Muir RK; Kabeche S; Yoo E; Yeo T; Lam G; Zhang H; Almaliti J; Berger G; Faucher FF; Lin G; Gerwick WH; Yeh E; Fidock DA; Bogyo M
    ACS Infect Dis; 2023 Oct; 9(10):2036-2047. PubMed ID: 37712594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
    Stokes BH; Yoo E; Murithi JM; Luth MR; Afanasyev P; da Fonseca PCA; Winzeler EA; Ng CL; Bogyo M; Fidock DA
    PLoS Pathog; 2019 Jun; 15(6):e1007722. PubMed ID: 31170268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Small Molecules Disrupting the Ubiquitin Proteasome System in Malaria.
    Mata-Cantero L; Chaparro MJ; Colmenarejo G; Cid C; Cortes Cabrera A; Rodriguez MS; Martín J; Gamo FJ; Gomez-Lorenzo MG
    ACS Infect Dis; 2019 Dec; 5(12):2105-2117. PubMed ID: 31644867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarials: Novel proteasome inhibitor combats malaria.
    Crunkhorn S
    Nat Rev Drug Discov; 2016 Apr; 15(4):232-3. PubMed ID: 27032831
    [No Abstract]   [Full Text] [Related]  

  • 18. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First homology model of Plasmodium falciparum glucose-6-phosphate dehydrogenase: Discovery of selective substrate analog-based inhibitors as novel antimalarial agents.
    Alencar N; Sola I; Linares M; Juárez-Jiménez J; Pont C; Viayna A; Vílchez D; Sampedro C; Abad P; Pérez-Benavente S; Lameira J; Bautista JM; Muñoz-Torrero D; Luque FJ
    Eur J Med Chem; 2018 Feb; 146():108-122. PubMed ID: 29407943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.
    Hsu HC; Li D; Zhan W; Ye J; Liu YJ; Leung A; Qin J; Crespo B; Gamo FJ; Zhang H; Cui L; Roth A; Kirkman LA; Li H; Lin G
    Nat Commun; 2023 Dec; 14(1):8302. PubMed ID: 38097652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.